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Flexible access to conformationally-locked bicyclic
morpholines†
Rachael Bogacki,a Duncan M. Gill,*b William J. Kerr,*a Scott Lamont,c
John A. Parkinsona and Laura C. Patersona
A preparatively accessible route to a series of conformationally-
locked bicyclicmorpholines has been developed.This flexible approach
allows for diversification in order for a small array of lead-like scaﬀolds
to be synthesised from readily available key building blocks.
Through an appreciable range of recent endeavours, bridged hetero-
cycles have emerged as desirable synthetic targets within the
pharmaceutical industry. More specifically, molecules containing
the bispidine (1; X = CH2; Fig. 1) and oxabispidine (1; X = O) unit
have become increasingly popular due to their evolving range of
therapeutic attributes.1 In relation to this, we have recently disclosed
a convenient, modular, and amenable route for the synthesis of a
range of chiral, optically-enriched bicyclic oxabispidine structures.2
Our preparative approach embedded specific key building blocks
into the desired molecular scaﬀold and, in turn, exploited an
intramolecular Mannich reaction (IMR) at the heart of our overall
synthetic strategy. In this regard, using emerging preparative routes
that have allowed the systematic exploration of chemical space,
MacLellan and Nelson have very recently established a conceptual
framework for analysing, planning, and extending synthetic
approaches to diverse lead-like scaﬀolds,3 and, indeed, highlighted
the applicability of our methods for access to the aforementioned
series of flexibly functionalised oxabispidines.2 Following on from
this, based on their potential therapeutic properties and driven by
the lack of flexible methods for their preparation,4 our extended
studies in this area have focused on strategies towards a series of
diﬀerentially-functionalised, strained, and synthetically more
challenging bridged bicyclic morpholines, such as 2. Moreover,
our approaches here aimed to further underpin the recently
developing concepts around the enhancement of preparative
eﬀectiveness aligned with lead-like diversity.3
Our general preparative approach towards the synthesis
of such bridged morpholine units is illustrated in Fig. 2. Key
oxazine 5, bearing a pendant electrophilic unit within the
structure, will be selectively cyclised to compounds of structure
type 6; intermediates of type 5 will be synthesised from com-
mercially available glycidol 3 and readily prepared amine acetal
4 as the key starting units. Overall, the synthetic approach
described herein allows for diversification at the 2, 6, and 7
positions of the overall bridged morpholine scaﬀold.
According to this proposed strategy, our initial target molecule
was aldehyde 10. As noted above, the synthesis begins with
commercially available glycidol, 3, which was protected prior to
undergoing ring opening with amine acetal 4 (Scheme 1). The
addition of sub-stoichiometric quantities of protic acid5 resulted in
eﬃcient formation of core morpholine acetal 8. Alcohol deprotec-
tion and subsequent oxidation, under Swern conditions, delivered
the desired aldehyde 10 in high overall yield.
With aldehyde 10 now accessible on good scale, the installa-
tion of the additional functionality required for access to the
Fig. 1 Bridged bicyclic heterocycles.
Fig. 2 General preparative approach.
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[3.2.1] bridged bicyclic structure 15 was investigated (Scheme 2).
Following appreciable Wittig optimisation, Barbier conditions were
employed to providemorpholine derivative 11 in an acceptable 59%
yield. Subsequently, an amine protecting group switch was carried
out in order to facilitate the elimination of methanol and install the
desired double bond in 12.2aHydroboration–oxidation then gave 13,
which, after further oxidation, delivered cyclisation precursor 14.
Following the screening of a variety of Brønsted acids, it was found
that p-toluenesulfonic acid in the presence of methanol facilitated
the key 5-exo-trig cyclisation process to deliver the targeted bridged
bicyclic morpholine scaffold in a pleasing 71% yield.
Analysis of NMR data revealed that our key cyclisation process
was completely diastereoselective, with compound 15 being obtained
as a single diastereomer. In order to authenticate the relative stereo-
chemistry, NOESY experiments were performed; interpretation
of the nOe interactions established that the bridging oxygen, the
methoxy unit, and the alcohol functionality were situated on the
same face of the bridged bicyclic structure, as shown in Fig. 3.
With the overall aim of targeting a variety of bridgedmorpholine
units, the developed synthetic approach allows for points of struc-
tural diversification to be introduced late in the synthetic pathway,
leading to maximised preparative eﬃciencies. For example, 15 was
converted into the corresponding ketone 16 (Scheme 3). Subsequent
nucleophilic addition with methylmagnesium chloride produced
derivative 17 in a good 72% yield and as a single diastereomer.
With the cyclisation approach to the novel bridged bicyclic
morpholine structures established, our studies continued towards
the preparation of more heavily substituted analogues. Envisaging
that our developed synthetic pathway would be amenable to
further substitution on the ethylene bridge, the previously synthe-
sised aldehyde 10 was reacted with methylmagnesium chloride to
produce alcohol 18 in excellent yield (Scheme 4). Following oxida-
tion, the previously described amine protecting group switch and
elimination were carried out to deliver compound 20. Wittig
olefination, followed by a hydroboration–oxidation sequence pro-
duced alcohol 22, which, on further oxidation, delivered cyclisation
precursor 23, all in good yields. We were then pleased to realise
that our previously developed cyclisation protocol also facilitated
the formation of the alternative bridgedmorpholine unit, although
this time as a mixture of diastereomers (24/25, 7 : 3 dr).
Evidence from NOESY NMR experiments revealed that within
themajor diastereomer (24) the bridging oxygen, themethoxy unit,
the methyl group, and the alcohol moiety were all positioned on
Scheme 1 Preparation of aldehyde 10. Reaction conditions (a) TIPSCl, imidazole,
THF, r.t., 97%; (b) 4, ethanol, reflux, 100%; (c) p-TsOH (40 mol%), 115 1C, 87%;
(d) TBAF, THF, 0 1C, 90%; (e) (COCl)2, DMSO, NEt3, CH2Cl2, 60 1C to 0 1C, 98%.
Scheme 2 Preparation of bridged bicyclic morpholine 15. Reaction conditions
(a) BrPPh3Me, KHMDS, THF, 78 1C to r.t., 59%; (b) (i) BnCO2Cl, CH2Cl2, r.t.; (ii) p-TsOH
(40 mol%), toluene, reflux, 67%; (c) (i) 9-BBN, THF, r.t.; (ii) 30% H2O2, 3 M NaOH, 0 1C,
68%; (d) DMP, CH2Cl2, r.t., 75%; (e) p-TsOH (10 mol%), MeOH, MeCN, r.t., 71%.
Fig. 3 NMR-based structural elucidation of 15.
Scheme 3 Preparation of alternative bridged bicyclic morpholines.
Scheme 4 Preparation of bridged bicyclic morpholines 24/25. Reaction conditions
(a) MeMgCl, LiCl, THF, 0 1C, 93%; (b) (COCl)2, DMSO, NEt3, CH2Cl2,60 1C to r.t., 75%;
(c) (i) BnCO2Cl, CH2Cl2, r.t.; (ii) p-TsOH (40 mol%), toluene, reflux, 56%; (d) BrPPh3Me,
t-BuOK, THF, 0 1C to r.t., 87%; (e) (i) 9-BBN, THF, r.t.; (ii) 30% H2O2, 3 M NaOH, 0 1C,
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the same face of the bridged bicyclic morpholine (Fig. 4).
Alternatively, analysis of the minor diastereomer (25) led to the
identification of the structure with epimeric alcohol functionality.
These analyses indicate that the hydroboration of 21 had
proceeded in a facially selective fashion. Indeed, the observed
mode of reaction is consistent with the studies of and associated
models established by Still and Barrish relating specifically to
the diastereoselective hydroboration of 1,1-disubstituted allylic
alcohols and ethers, where high levels of anti-selectivity were
found with 9-BBN.6 This anti-stereoselective outcome with sub-
strate 21 to give 22A is illustrated in Fig. 5. Turning to the further
stereochemistry obtained post-cyclisation of 14 and 23, the
transition state depicted in Fig. 6 is proposed. In this model,
neighbouring interaction with the bridging morpholine oxygen
leads to conformational restriction of the activated aldehyde
and, in turn, stereoselectivity in the cyclisation to install the
carbinol unit. In the cyclisation of 14 (R = H) only stereoisomer
15 is observed; in contrast, the process with 23 is less selective,
potentially due to competing interactions between the R (Me)
group and the activated carbonyl, leading to both 24 and 25
(7 : 3). Following cyclisation, methanol approaches on the least
hindered face of the resultant iminium ion.
Returning to the preparative studies and in order to extend
overall substitution levels, oxidation of 24/25 provided ketone
analogue 26 (Scheme 5). In a similar process to that described
with structure 16, ketone 26 was reacted with methylmagnesium
chloride to deliver alcohol derivative 27 as a single diastereomer.
In summary, we have established a preparatively flexible
strategy for access to a series of novel bridged morpholine units.
Moreover, it is believed that both the use of readily available
starting materials and the ability to perform late-stage structural
manipulations further enhance the eﬀectiveness of the approach
described. Indeed, it is important to highlight that the directing
stereocentre within this overall sequence is provided by the
glycidol building block (3) at the very outset of our synthetic
pathway. Accordingly, this overall approach has the potential to
enhance the available synthetic strategies towards diverse lead-
like scaﬀolds for application in a range of therapeutic areas.
Further studies towards the establishment of associated asym-
metric routes are currently on-going within our laboratories.
We would like to thank the EPSRC and AstraZeneca for
funding. Mass spectrometry data were acquired at the EPSRC
UK National Mass Spectrometry Facility at Swansea University.
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Fig. 4 NMR-based structural elucidation of compounds 24 and 25.
Fig. 5 anti-Diastereoselective hydroboration of 21.
Fig. 6 Proposed model for cyclisation stereoselectivity.
Scheme 5 Preparation of alternative bridged bicyclic morpholines.
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